Clinical Trials Browser

OTHER × Breast Neoplasms, Male × Trastuzumab × Clear all

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00085020 2020-08-03

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase 2 Completed

30 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00971737 2019-04-24

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

63 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00847171 2018-09-26

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Phase 2 Completed

20 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00331552 2017-07-26

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

30 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00093808 2017-03-06

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

47 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00182793 2017-02-23

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00824733 2016-01-14

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Phase NA Completed

BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00054470 2012-06-29

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male